Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Vera Therapeutics (VERA) to $97 from $75 and keeps an Outperform rating on the shares. Voyxact’s pricing at $30,000 per vial, totaling $390,000 annually, exceeds investor expectations and the firm’s updated IgAN market model now forecasts $12.5B in peak worldwide sales, with $9.4B from the U.S. alone, the analyst says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics price target raised to $73 from $60 at TD Cowen
- Optimistic Buy Rating for Vera Therapeutics Amid Strategic Advancements and Financial Projections
- Vera Therapeutics price target raised to $99 from $52 at JPMorgan
- Strategic Positioning and Market Opportunities Favor Vera Therapeutics: A Buy Recommendation
- Vera Therapeutics rises 19.2%